Review



anti-mouse ifnar1 neutralizing antibody be0241  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bio X Cell anti-mouse ifnar1 neutralizing antibody be0241
    a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or <t>anti-IFNAR1</t> neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.
    Anti Mouse Ifnar1 Neutralizing Antibody Be0241, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti-mouse+ifnar1+neutralizing+antibody+be0241/pmc09156717-322-1-11?v=Bio+X+Cell
    Average 90 stars, based on 1 article reviews
    anti-mouse ifnar1 neutralizing antibody be0241 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer"

    Article Title: STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    Journal: Nature Communications

    doi: 10.1038/s41467-022-30568-1

    a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or anti-IFNAR1 neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.
    Figure Legend Snippet: a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or anti-IFNAR1 neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.

    Techniques Used: Western Blot, CRISPR, Control, Knock-Out, Serial Dilution, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Two Tailed Test, MANN-WHITNEY



    Similar Products

    anti-mouse ifnar1 neutralizing antibody be0241  (Bio X Cell)
    90
    Bio X Cell anti-mouse ifnar1 neutralizing antibody be0241
    a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or <t>anti-IFNAR1</t> neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.
    Anti Mouse Ifnar1 Neutralizing Antibody Be0241, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti-mouse+ifnar1+neutralizing+antibody+be0241/pmc09156717-322-1-11?v=Bio+X+Cell
    Average 90 stars, based on 1 article reviews
    anti-mouse ifnar1 neutralizing antibody be0241 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or anti-IFNAR1 neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    doi: 10.1038/s41467-022-30568-1

    Figure Lengend Snippet: a Western blots for STING and VINCULIN in CRISPR/Cas9 control and STING knockout BP tumor cells (BP-sgControl and BP-sgSTING). Representative blots of two independent experiments are shown. b CellTiter-Glo analysis showing cell viability of BP-sgControl and BP-sgSTING cells after 3 days of treatment with serial dilution of olaparib ( n = 3). c Flow cytometry analysis of mouse BMDMs treated with DMSO vehicle control, olaparib (OL, 5 μM), 50% BP-sgSTING-CM, or 50% BP-sgSTING/OL-CM for two days ( n = 3). d ELISA analysis of IFNβ in media from BP-sgControl or BP-sgSTING cells with or without 2 days of olaparib treatment ( n = 7). e and f RT-qPCR analysis of Ccl5 ( e ) and Cxcl10 ( f ) in BP-sgControl and BP-sgSTING cells treated with or without olaparib for 2 days (BP-sgControl, n = 4; BP-sgSTING, n = 3). g Tumor growth (left) and survival (right) of BP-sgControl tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 13; Olaparib, n = 7; DMXAA, n = 9; Olaparib + DMXAA, n = 14. Right, Control, n = 8; olaparib, n = 5; DMXAA, n = 6; olaparib + DMXAA, n = 9. h Tumor growth (left) and survival (right) of BP-sgSTING tumor-bearing FVB mice treated with olaparib (50 mg/kg, IP, QD), DMXAA (10 mg/kg, IP) or olaparib + DMXAA. Median survivals are shown in parentheses. Left, Control, n = 24; olaparib, n = 11; DMXAA, n = 9; olaparib + DMXAA, n = 19. Right, Control, n = 13; olaparib, n = 7; DMXAA, n = 6; olaparib + DMXAA, n = 11. i and j BP-sgControl ( i ) and BP-sgSTING ( j ) tumor growth in FVB mice treated with olaparib + DMXAA with or without anti-CD8 or anti-IFNAR1 neutralizing antibodies ( n = 6 per condition). Data are presented as mean ± SEM. One-way ANOVA ( c, e , and f ). Two-tailed Mann–Whitney test ( d ). Two-way ANOVA for tumor growth ( g )–( j ). Log-rank Mantel–Cox test for survival ( g and h ). ns, not significant. Source data are provided as a Source Data file.

    Article Snippet: For IFNAR1 blockade, anti-mouse IFNAR1 neutralizing antibody (200 μg/mouse; clone MAR1-5A3; BioXcell, # BE0241) was administered via IP 72 h and 24 h before start of the combination therapy (olaparib + DMXAA) and every 3 days thereafter.

    Techniques: Western Blot, CRISPR, Control, Knock-Out, Serial Dilution, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Two Tailed Test, MANN-WHITNEY